Which is better, ALNY or GMAB?

On the Buffett-Fit framework, Alnylam Pharmaceuticals, Inc. (ALNY) currently grades higher than GMAB — 58/100 (C grade) vs 65/100 (C). That said, "better" depends on which framework you trust — ALNY wins on Benjamin Graham, Philip Fisher, Peter Lynch, Charlie Munger, and Terry Smith; GMAB wins on Warren Buffett and Joel Greenblatt. The full pillar breakdown is on this page.

Should I buy ALNY or GMAB?

This page is an educational comparison, not investment advice. Both ALNY and GMAB are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is ALNY better than GMAB for value investing?

On the Buffett-style value-investing framework, ALNY currently grades higher — 65/100 vs 58/100, a 7-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between ALNY and GMAB on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). ALNY currently scores 58/100 (C grade); GMAB scores 65/100 (C grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, ALNY or GMAB?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. ALNY and GMAB are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, ALNY or GMAB?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are ALNY and GMAB both Healthcare stocks?

Yes — both Alnylam Pharmaceuticals, Inc. (ALNY) and Genmab A/S (GMAB) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this ALNY vs GMAB comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Alnylam Pharmaceuticals

Genmab A/S

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

ALNY

Market cap

$39.71B

Sector

Healthcare

GMAB

Genmab A/S

Market cap

$16.5B

Sector

Healthcare

Overall winner

Alnylam Pharmaceuticals ALNY

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	ALNY	GMAB	Winner
Warren Buffett	58C	65C	GMAB
Benjamin Graham	80D	64C	ALNY
Philip Fisher

Side-by-side metrics

Metric	ALNY	GMAB
Market cap	$39.71B	$16.5B
P/E (TTM)	66.1x	6.2x
EV/EBIT	75.5x	12.0x
ROIC (TTM)	19.66%	43.78%
Gross margin	80.89%	93.88%
Net margin	13.46%	18.23%
Revenue CAGR 5y	44.82%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

ALNY leads on

EPS CAGR 5y38.42%vs -23.48%+161%
Revenue CAGR 5y44.82%vs -18.45%+141%
Market cap$39.71Bvs $16.5B+58%

GMAB leads on

More like ALNY

ALNY vs IDXX ALNY vs LMAT ALNY vs MTD ALNY vs HALO ALNY vs HRMY ALNY vs RPRX

More like GMAB

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.